Solid tumors and hematologic malignancies (AML, MDS, DLBCL)
Conditions
Interventions
AS-0141 will be orally administered twice a day (5 days on/2 days off, or everyday) in a 21-day treatment cycle. The starting dose will be 40 mg/day.
Sponsors
Arimura Akinori
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Aged >18 years at time of informed consent - Histlogically confirmed solid tumors, AML, MDS, or DLBCL for which no standard therapy is available - Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) <= 1 (solid tumors and DLBCL) or <= 2 (AML and MDS) - Life expectancy at least 3 months (90days)
Exclusion criteria
Exclusion criteria: - Patient with known high microsatellite instability(MSH-H) - Any of the following complicating desease 1) Uncontrolled diabetes 2) Interstitial pneumonia, pulumonary fibrosis, radiation pneumonia (including history) 3) Active infection disease requiring systemic treatment such as antimicrobial agent, antivirus agent 4) AML patients with leukocytosis over 30,000/mm^3 in peripheral leukocyte count - Any of following serious cardiac or cardiovascular condition 1) Congestive heart failure 2) Class III/ IV heart failure according to the New York Heart Association [NYHA] criteria 3) Ischemic myocardial disease (angina pectoris which needs treatment or revascularization, miocardinal infarction, unstable and symptomatic ischemic heart disease, etc) within 6 months before study drug administration 4) Uncontrolled cardiac arrhythmia (including atrial flutter/fibrillation, ventricular fibrillation, or ventricular tachycardia) 5) Uncontrolled hypertension 6) Ischemic cerebrovascular accident (history of transient ischemic attack, arterial blood circulation reconstruction, etc.)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Dose limiting toxicity | — |
Contacts
Public ContactAkinori Arimura
Carna Biosciences, Inc.
Outcome results
None listed